Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026)

Rigel Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $24.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 46.62% year-over-year to $24.4 million; the trailing twelve-month figure through Mar 2026 stood at $24.4 million (down 46.62% YoY), and the FY2025 full-year result was $40.6 million, down 28.49% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $24.4 million, down from $40.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $56.7 million in Q4 2024, with the low at $24.4 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $38.6 million, with a median of $40.3 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 67.93% in 2022 and surged 79.45% in 2023.
• Tracing RIGL's Cash & Equivalents over 5 years: stood at $24.5 million in 2022, then soared by 34.04% to $32.8 million in 2023, then soared by 73.08% to $56.7 million in 2024, then slipped by 28.49% to $40.6 million in 2025, then tumbled by 39.84% to $24.4 million in 2026.
• The last three Cash & Equivalents figures came in at $24.4 million (Q1 2026), $40.6 million (Q4 2025), and $48.5 million (Q3 2025), per Business Quant data.

Peer Comparison